{
    "diseases": [
      {
        "name": "Myelodysplastic Syndrome (MDS)",
        "description": "Pre-malignant condition, primarily disease of the old people.",
        "investigations": [
          "Similar to aplastic anaemia, plus analysis of 5q deletion."
        ],
        "treatments": [
          {
            "Pharmacological Treatment": [
              {
                "class": "B",
                "name": "Blood transfusion",
                "reason": "for symptomatic treatment"
              },
              {
                "class": "S",
                "name": "azacitidine (SC)",
                "weight": "75mg/m2",
                "frequency": "24 hourly for 7 days, repeat after every 28 days"
              }
            ]
          }
        ]
      },
      {
        "name": "Bleeding Disorders",
        "subcategories": [
          {
            "name": "Hereditary Bleeding Disorders",
            "description": "Includes haemophilia A and B, Von Willebrand disease",
            "subcategories": [
              {
                "name": "Haemophilia",
                "description": "Haemophilia is an inherited, X-linked lifelong bleeding disorder which affects males almost exclusively.",
                "clinical_presentation": [
                  "Spontaneous muscle and joint bleeding without injury",
                  "Prolonged bleeding after injury",
                  "Epistaxis and easy bruising",
                  "Complication includes arthropathy and disability"
                ],
                "subtypes": [
                  {
                    "name": "Haemophilia A (Factor VIII deficiency)",
                    "description": "Is the most common of the hereditary clotting factor deficiencies and are caused by deficiency of factor VIII."
                  },
                  {
                    "name": "Haemophilia B (Factor IX deficiency)",
                    "description": "It is caused by deficiency of clotting factor IX. Presentation as in Haemophilia A, this is less common 20%."
                  }
                ],
                "classification": [
                  {
                    "severity": "Severe",
                    "factor_VIII_level": "<1% of normal",
                    "factor_IX_level": "≤ 0.01 U/ml",
                    "clinical_features": [
                      "Spontaneous haemorrhage",
                      "Frequent spontaneous haemarthrosis"
                    ]
                  },
                  {
                    "severity": "Moderate",
                    "factor_VIII_level": "2-5% of normal",
                    "factor_IX_level": "0.01-0.05 U/ml",
                    "clinical_features": [
                      "Haemorrhage secondary to trauma or surgery",
                      "Occasional spontaneous haemarthrosis"
                    ]
                  },
                  {
                    "severity": "Mild",
                    "factor_VIII_level": "5-40% of normal",
                    "factor_IX_level": "5-40% of normal",
                    "clinical_features": [
                      "Haemorrhage post trauma or surgery",
                      "Rare spontaneous haemarthrosis"
                    ]
                  }
                ],
                "investigations": [
                  "Prolonged aPTT but normal PT and Platelets counts",
                  "Confirm by factor VIII or IX assay"
                ],
                "treatments": [
                  {
                    "Non-Pharmacological Treatment": [
                      "Avoid I.M injections and use small gauge needles if necessary",
                      "Inform the patient and parents thoroughly on the problem, and provide means of alerting other medical/pharmaceutical personnel",
                      "Genetic counselling",
                      "For Acute Bleeding episodes (RICE): Rest, Ice/cold pack – 5 minutes on, 10 min off, Compression and Elevate the joint.",
                      "For haemarthrosis – AVOID incising or aspiration of the affected joint. Treat by replacing the specific factor e.g factor 8 or 9 concentrate if available or FFP (10-15ml/kg), joint support and tabs Paracetamol for pain."
                    ]
                  },
                  {
                    "Pharmacological Treatment": [
                      {
                        "type": "Haemophilia A (Factor VIII Deficiency) no Inhibitor",
                        "severity": "Minor bleed",
                        "class": "S",
                        "name": "Factor VIII (IV)",
                        "dose": "20–40 IU/kg"
                      },
                      {
                        "type": "Haemophilia A (Factor VIII Deficiency) no Inhibitor",
                        "severity": "Major bleed",
                        "class": "S",
                        "name": "Factor VIII (IV)",
                        "dose": "50–100 IU/kg 12 hourly for 3-5 days or until bleeding stops",
                        "note": "Expected response: 1 IU/kg = 2% rise in factor VIII level. Half-life Factor VIII: 8–24 hours"
                      },
                      {
                        "type": "Haemophilia B (Factor IX deficiency) no inhibitor",
                        "severity": "Minor bleed",
                        "class": "S",
                        "name": "Factor IX (IV)",
                        "dose": "20-50 IU/kg"
                      },
                      {
                        "type": "Haemophilia B (Factor IX deficiency) no inhibitor",
                        "severity": "Major bleed",
                        "class": "S",
                        "name": "Factor IX (IV)",
                        "dose": "100 IU/kg",
                        "note": "Expected response: 1 IU/kg = 1.5 rise in the factor IX level. Half-life Factor IX: 16–24 hours"
                      },
                      {
                        "class": "D",
                        "name": "Fresh frozen plasma (FFP)",
                        "condition": "Can be used where factor concentrate is unavailable.",
                        "dose": "Average dose 10-15 mls/kg"
                      },
                      {
                        "note": [
                          "If there is no response to appropriate replacement therapy tests for inhibitors (an inhibitor is formed when one develops antibodies against factor concentrates)",
                          "Detection of inhibitor is by aPTT mix study and confirmed by Bethesda assay (BU)"
                        ]
                      },
                      {
                        "name": "Factor VIII Inhibitor Management Options",
                        "options": [
                          "High dose factor concentrate infusion",
                          "Use by-pass agent like FEIBA (Factor Eight Inhibitor By-passing Agent)",
                          "Immune tolerance induction therapy (ITI)",
                          "In case of emergency surgery consider plasmapheresis",
                          "Adjuvant antifibrinolytic agents eg Tranexamic acid can be used with either of the above"
                        ]
                      }
                    ]
                  }
                ],
                "notes": [
                  "All patients suspected with haemophilia A or B refer to higher facility with adequate expertise or consult haematology Unit.",
                  "Children with severe haemophilia are recommended to be on low dose prophylaxis of factor concentrate.",
                  "Male circumcision should be done at a hospital where factor concentrate is available. Concentrate should be given before and after the procedure."
                ]
              },
              {
                "name": "Von Willebrand Disease (VWD)",
                "description": "Von Willebrand Disease is an inherited disease due to deficiency of vWF. It is the commonest bleeding disorder in the population especially in women.",
                "clinical_presentation": [
                  "History of easy bruising",
                  "Menorrhagia",
                  "Gum bleeding",
                  "Joint bleeding in severe cases"
                ],
                "investigations": [
                  "Confirmatory test: VWF level assay",
                  "PT, aPTT, and platelet count are normal except in severe cases."
                ],
                "treatments": [
                  {
                    "Pharmacological Treatment": [
                      {
                        "class": "C",
                        "name": "etamsylate (PO)",
                        "dose": "500mg 8 hourly until the bleeding stops"
                      },
                      {
                        "class": "C",
                        "name": "tranexamic acid (PO)",
                        "dose": "500mg 8 hourly until bleeding is stopped"
                      },
                      {
                        "class": "S",
                        "name": "Desmopressin (IV)",
                        "dose": "0.3µg/kg IV stat. Max. Dose 20µg"
                      }
                    ]
                  }
                ],
                "notes": [
                  "Patient unresponsive to DDVAP may be treated with virus-inactivated vWF containing FVIII concentrate.",
                  "Never give Etamsylate or Tranexamic acid to patients bleeding per urethral."
                ]
              }
            ]
          },
          {
            "name": "Acquired Bleeding Disorders/Platelet Disorders",
            "subcategories": [
              {
                "name": "Disseminated Intravascular Coagulation (DIC)",
                "clinical_features": [
                  "Usually are related to the underlying disorder",
                  "Bleeding manifestation",
                  "Extensive organ dysfunction",
                  "Shock, renal cortical ischemia, coma, delirium and focal neurological symptoms"
                ],
                "treatments": [
                  {
                    "Pharmacological Treatment": [
                      "Rapid and appropriate treatment of the underlying disorder including antibiotics for infection",
                      "Surgical debridement of necrotic tissues",
                      "Chemotherapy for malignant causes",
                      "Evacuation of dead fetus",
                      "Platelets transfusion for thrombocytopenia",
                      "Fresh frozen plasma (FFP) for coagulation factor depletion",
                      "Monitor prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin (aPTT), platelet count and fibrinogen"
                    ]
                  }
                ],
                "notes": [
                  "If patient is not bleeding Platelets concentrate is contraindicated.",
                  "If DIC is severe enough to cause multiorgan dysfunction, management in an intensive care unit is required."
                ]
              },
              {
                "name": "Idiopathic Thrombocytopenic Purpura (ITP)",
                "clinical_features": [
                  "Long history of Purpura, menorrhagia, epistaxis and gingival haemorrhage",
                  "Intracerebral haemorrhage occurs infrequently but is the most cause of death",
                  "Overt bleeding is rare unless thrombocytopenia severe (less than 10 X 109/L)"
                ],
                "note": "A palpable spleen strongly suggests that ITP is NOT the cause for thrombocytopenia.",
                "treatments": [
                  {
                    "Non-Pharmacological Treatment": [
                      "Patients with platelet counts over 50 X109/L usually do not have spontaneous bleeding and may undergo invasive procedure.",
                      "Emergency treatment of acute bleeding caused by severe thrombocytopenia need immediate platelet transfusion."
                    ]
                  },
                  {
                    "Pharmacological Treatment": [
                      {
                        "class": "A",
                        "name": "prednisolone (PO)",
                        "dose": "1mg/kg/day for 3–6 weeks, then taper 10mg weekly",
                        "condition": "For all patients with platelet counts below 30 X109/L"
                      },
                      {
                        "class": "B",
                        "name": "dexamethasone (IV)",
                        "dose": "40mg in 500ml Normal saline running for 4 hours once a day for 4 days"
                      },
                      {
                        "class": "S",
                        "name": "human Immunoglobulin G (IV)",
                        "dose": "0.4g/kg/day for 5 days",
                        "condition": "If no response"
                      },
                      {
                        "class": "S",
                        "name": "human Immunoglobulin G (IV)",
                        "dose": "1g/kg/day for 2 days followed by immediate platelet transfusion",
                        "condition": "If no response"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    ]
  }
  